JPRN-UMIN000050553招募中Unknown
Improved survival with osimertinib in patients with advanced EGFR-mutated non-small cell lung cancer aged 75 years or older: a subset of elderly patients in TREAD 01 - Improved survival with osimertinib in patients with advanced EGFR-mutated non-small cell lung cancer aged 75 years or older: a subset of elderly patients in TREAD 01
适应症
试验速览
- 阶段
- Unknown
- 状态
- 招募中
- 入组人数
- 300
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Exclusion criteria for this study include: de novo EGFR T790M mutation, opt-outs who refused to give informed consent, insufficient data extraction such as missing details of previous cancer treatment at other hospitals or individual patient data, simultaneous or metachronous double cancers other than in situ/intramucosal cancer cured by local treatment or endoscopic lesions diagnosed as in situ cancer, or disease-free for 5 years or less.
研究者
相似试验
已完成
不适用
Observational study of osimertinib for patients with locally advanced/metastatic non-small cell lung cancer who are harboring T790M mutation detected by liquid biopsy and whose disease has progressed with previous EGFR-TKI therapy(WJOG8815LFS)EGFR mutation positive advanced or metastatic NSCLCJPRN-UMIN000034682West Japan Oncology Group33
已完成
不适用
A phase II study of osimertinib in patients with poor performance status and EGFR mutation T790M-positive non-small-cell lung cancerPatients with poor performance status and EGFR mutation T790M-positive non-small-cell lung cancerJPRN-UMIN000027655Division of Thoracic Oncology, Shizuoka cancer center18
招募中
不适用
Phase II study of osimertinib in patients with non-small cell lung cancer who acquired resistance to afatinibon-small cell lung cancerJPRN-UMIN000028166Asahikawa Medical University Hospital50
招募中
4 期
Efficacy study of osimertinib in treatment-naïve patients with EGFR mutant NSCLC according to TP53 mutational status (TEMPLE-2)2024-517424-18-00Fondazione Policlinico Universitario Agostino Gemelli IRCCS54
进行中（未招募）
2 期
A Phase 2 Study of Osimertinib in combination with Platinum-pemetrexed in patients with EGFR-mutated Advanced non-small cell Lung cancer.on-squamous non-small cell lung cancerJPRN-jRCTs031180226Kobayashi Kunihiko66